Eisai licenses SymBio's bendamustine in S Korea and Singapore

Eisai has licensed fellow Japanese drugmaker SymBio's non-Hodgkin's lymphoma drug SyB L-0501 (bendamustine HCl) in both South Korea and  Singapore.

The estimated annual number of newly-diagnosed patients with NHL in  South Korea and Singapore is 2,300 and 300, respectively. It is  well-known that a large number of these patients are prone to relapse  after responding to initial treatment, making further treatment  difficult despite a long overall survival period.

Through this partnership, SymBio will accelerate expansion of its  pharmaceutical business in Asia-Pacific with bendamustine as its first  product in the region. Eisai will begin its full-scale business  deployment in the oncology area in Asia, including South Korea and  Singapore, with the addition of bendamustine to its in-house pipeline of  cancer products.